Skip to main content
Journal cover image

Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.

Publication ,  Journal Article
Verma, S; Dent, S; Chow, BJW; Rayson, D; Safra, T
Published in: Cancer Treat Rev
August 2008

Anthracyclines demonstrate significant disease activity in breast cancer and are a key component of therapy in both early and advanced disease. It has been long recognized that these agents are associated with cumulative dose-related cardiotoxicity that often limits their utility at the time of disease recurrence. The risk of anthracycline-associated cardiotoxicity appears to be highest in women with HER2-overexpressing breast cancer previously having received an adjuvant anthracycline-trastuzumab regimen. Clinical trials have demonstrated that pegylated liposomal doxorubicin (PLD) is equally active but associated with a significantly lower risk of cardiotoxicity compared with conventional doxorubicin whether administered as monotherapy or in combination with trastuzumab. Thus, PLD can be effectively and safely substituted for conventional doxorubicin, allowing retreatment with an anthracycline in the metastatic setting. PLD has also been shown to improve time to tumor progression when used as maintenance therapy. These data, when coupled with the need to maintain efficacy and reduce cardiotoxicity in the management of metastatic breast cancer, support the use of PLD in the metastatic setting, as well as support the rationale for evaluating PLD as adjuvant therapy.

Duke Scholars

Published In

Cancer Treat Rev

DOI

ISSN

0305-7372

Publication Date

August 2008

Volume

34

Issue

5

Start / End Page

391 / 406

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Humans
  • Female
  • Doxorubicin
  • Disease Progression
  • Breast Neoplasms
  • Anthracyclines
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Verma, S., Dent, S., Chow, B. J. W., Rayson, D., & Safra, T. (2008). Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev, 34(5), 391–406. https://doi.org/10.1016/j.ctrv.2008.01.008
Verma, Shailendra, Susan Dent, Benjamin J. W. Chow, Daniel Rayson, and Tamar Safra. “Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.Cancer Treat Rev 34, no. 5 (August 2008): 391–406. https://doi.org/10.1016/j.ctrv.2008.01.008.
Verma S, Dent S, Chow BJW, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008 Aug;34(5):391–406.
Verma, Shailendra, et al. “Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.Cancer Treat Rev, vol. 34, no. 5, Aug. 2008, pp. 391–406. Pubmed, doi:10.1016/j.ctrv.2008.01.008.
Verma S, Dent S, Chow BJW, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008 Aug;34(5):391–406.
Journal cover image

Published In

Cancer Treat Rev

DOI

ISSN

0305-7372

Publication Date

August 2008

Volume

34

Issue

5

Start / End Page

391 / 406

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Humans
  • Female
  • Doxorubicin
  • Disease Progression
  • Breast Neoplasms
  • Anthracyclines
  • 3211 Oncology and carcinogenesis